The FDA has greenlit Lipfendra, a novel once-daily pill that sharply cuts LDL cholesterol, offering a new option for patients struggling with elevated 'bad' cholesterol—especially those who haven’t reached cholesterol goals with traditional treatments.
- Lipfendra reduces LDL cholesterol by almost 60%
- First oral PCSK9 inhibitor approved by FDA
- Targets patients with high cardiovascular risk and genetic cholesterol issues
What happened
The U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral pill in the PCSK9 inhibitor class designed to treat high LDL cholesterol. Unlike existing PCSK9 treatments that require injections, Lipfendra offers a once-daily oral dose. This marks a significant milestone in cholesterol management, particularly for those with hypercholesterolemia—the condition of having elevated low-density lipoprotein (LDL) cholesterol, often called 'bad' cholesterol.
Why it feels good
Moreover, the clinical trials showed Lipfendra does not carry the allergy risks sometimes seen with injectable alternatives. This safety profile, combined with its strong cholesterol-lowering effect, is a big step forward in making advanced cholesterol care more accessible and tolerable. The potential to significantly reduce cardiovascular events by better managing LDL cholesterol is an encouraging prospect for millions worldwide.
What to enjoy or watch next
Meanwhile, people interested in heart health should continue to monitor updates on new therapies and consult their healthcare providers about the best options for managing cholesterol. As medicine advances, combining lifestyle improvements with innovative drugs offers the best path to reducing heart disease risk and supporting overall wellbeing.